ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
$233.29
arrow_upward
+0.63%(+1.46) 1D
$233.41
arrow_upward
+0.05% (+0.12)bedtimeAfter hours
Closed: Oct 19, 4:00:01 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
$232.64
High
$236.54
Low
$231.26
Mkt. cap
31.22B
Avg. vol.
1.34M
Volume
0.00
P/E ratio
39.70
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.28
Shares outstanding
133.81M
No. of employees
2K
Open
$232.64
High
$236.54
Low
$231.26
Mkt. cap
31.22B
Avg. vol.
1.34M
Volume
0.00
P/E ratio
39.70
52-wk high
$495.55
52-wk low
$197.81
EPS
$5.88
Beta
0.28
Shares outstanding
133.81M
No. of employees
2K
News stories
From web sources and news partners
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.
CEOYvonne Greenstreet
Employees2.5K
FoundedJun 14, 2002
Headquarters-
SectorBiotechnology
Websitealnylam.com
Analyst ratings
Based on 23 analysts giving stock ratings to ALNY in the past 3 months
Strong buy
Buy
19
Hold
4
Sell
0
12-month forecast
Based on 23 Wall Street analysts offering 12 month price targets for ALNY in the last 3 months.
Highest
Current $233.29
$489.00 (+109.61%)
Average
$364.76 (+56.35%)
Lowest
$253.00 (+8.45%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Joon Lee UBS | Buy | Maintained | $354.00 | +51.7% | 10/16/2026 |
Derek Archila Wells Fargo | Hold | Maintained | $253.00 | +8.4% | 10/14/2026 |
Eric Joseph Citi | Buy | Maintained | $320.00 | +37.2% | 10/15/2026 |
Unknown Analyst Wells Fargo | Hold | Reiterated | $253.00 | +8.4% | 10/14/2026 |
Eliana Merle Barclays | Buy | Maintained | $450.00 | +92.9% | 10/13/2026 |
Tazeen Ahmad Bank of America Securities | Buy | Reiterated | - | - | 10/09/2026 |
Michael Ulz Morgan Stanley | Hold | Maintained | $300.00 | +28.6% | 10/09/2026 |
Luca Issi RBC Capital | Buy | Maintained | $345.00 | +47.9% | 10/08/2026 |
Olivia Brayer Cantor Fitzgerald | Hold | Maintained | $325.00 | +39.3% | 09/30/2026 |
Jessica Fye J.P. Morgan | Buy | Reiterated | $369.00 | +58.2% | 09/30/2026 |
Jeffrey Walch Bernstein | Buy | Maintained | $376.00 | +61.2% | 09/25/2026 |
Patrick Trucchio H.C. Wainwright | Buy | Reiterated | $455.00 | +95% | 09/21/2026 |
David Lebowitz BMO Capital | Buy | Maintained | $318.00 | +36.3% | 09/17/2026 |
Danielle Brill Truist Financial | Buy | Reiterated | - | - | 09/18/2026 |
Joseph Stringer Needham | Buy | Maintained | $357.00 | +53% | 09/17/2026 |
Faisal Khurshid Jefferies | Hold | Maintained | $260.00 | +11.4% | 09/08/2026 |
Cory Kasimov Evercore ISI | Buy | Maintained | $325.20 | +39.4% | 08/31/2026 |
Edward Tenthoff Piper Sandler | Buy | Reiterated | $489.00 | +109.6% | 08/31/2026 |
Paul Matteis Stifel Nicolaus | Buy | Maintained | $318.00 | +36.3% | 08/31/2026 |
Whitney Ijem Canaccord Genuity | Buy | Maintained | $429.00 | +83.9% | 08/28/2026 |
Unknown Analyst BMO Capital | Buy | Initiated | $318.00 | +36.3% | 08/18/2026 |
Martin Auster Raymond James | Buy | Maintained | $420.00 | +80% | 07/31/2026 |
Kostas Biliouris Oppenheimer | Buy | Maintained | $350.00 | +50% | 07/31/2026 |
Ritu Baral TD Cowen | Buy | Reiterated | $482.00 | +106.6% | 07/31/2026 |
Myles Minter William Blair | Buy | Maintained | - | - | 07/30/2026 |
Salveen Richter Goldman Sachs | Buy | Maintained | $550.00 | +135.8% | 06/25/2026 |
Unknown Analyst J.P. Morgan | Buy | Maintained | $420.00 | +80% | 05/20/2026 |
Unknown Analyst Citi | Buy | Initiated | $380.00 | +62.9% | 05/19/2026 |
William Pickering Bernstein | Buy | Reiterated | $447.00 | +91.6% | 05/01/2026 |
Tiago Fauth Raymond James | Hold | Maintained | $377.00 | +61.6% | 05/01/2026 |
Keay Nakae Chardan Capital | Buy | Reiterated | $425.00 | +82.2% | 05/01/2026 |
Next call in 9 days
Thu, Oct 29, 2:30 PM
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
- / $2.26
Revenue / Est. (USD)
- / 1.43B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 1.25B | 1.10B | 1.17B | 1.29B |
Cost of goods sold | 200.15M | 267.72M | 211.12M | 298.45M |
Cost of revenue | 200.15M | 267.72M | 211.12M | 298.45M |
Research and development expenses | 358.81M | 372.22M | 364.87M | 413.13M |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 322.08M | 325.37M | 322.55M | 347.92M |
Operating expense | 680.89M | 697.59M | 687.42M | 761.06M |
Total operating expenses | 881.04M | 965.32M | 898.54M | 1.06B |
Operating income | 367.98M | 131.72M | 268.64M | 231.44M |
Other non operating income | -74.15M | 92.98M | -4.30M | 273.00K |
EBT including unusual items | 238.97M | 161.14M | 221.65M | 177.81M |
EBT excluding unusual items | 278.12M | 121.99M | 221.65M | 177.81M |
Income tax expense | -12.12M | -25.28M | 15.66M | 13.31M |
Effective tax rate | -5.07% | -15.69% | 7.07% | 7.49% |
Other operating expenses | - | - | - | - |
Net income | 251.08M | 186.42M | 205.99M | 164.49M |
Net profit margin | 20.10% | 16.99% | 17.65% | 12.74% |
Earnings per share | 2.90 | 1.25 | 1.99 | 1.84 |
Interest and investment income | 28.68M | 26.63M | 26.60M | 28.14M |
Interest expense | -44.40M | -129.34M | -69.29M | -82.05M |
Net interest expenses | -15.72M | -102.71M | -42.69M | -53.91M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 381.78M | 145.22M | 282.19M | 245.34M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1